INTRODUCTION
Cutaneous T-cell lymphoma (CTCL)e is most commonly a clonal malignancy of epidermotropic T-lymphocytes, usually of the CD4+ phenotype, which presents with a spectrum of clinical manifestations including mycosis fungoides (MF) and the Sezary syndrome [1] . CTCL also encompasses the less common clinical entities such as pagetoid reticulosis (Woringer- 
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Kollop disease), suppressor (CD8+) T-cell lymphoma, granulomatous slack skin, peripheral T-cell lymphoma, adult T-cell leukemia/lymphoma, CD30+ large cell lymphoma, and lymphomatoid granulomatosis [2] . Evidence from immunophenotyping and T-cell receptor gene rearrangement studies supports the classification of these dermatoses as forms of CTCL [3] .
A relatively rare disease, CTCL has an incidence rate of four per 1,000,000. However, the incidence appears to have increased by a factor of at least 3.2 between the years 1973 and 1984 [4] . Several registries indicate that African-Americans have the highest incidence of CTCL, almost twice that of whites. Males are also twice as likely to be affected as females. Although risk increases with age, with most cases being diagnosed during the fifth and sixth decades of life, one-eighth of all cases are diagnosed in patients below the age of 40, with documented cases in childhood [5, 6] . Approximately 1,000 new cases of CTCL are diagnosed annually in the United States [2] . A recent population-based analysis of nine cancer registries also shows that median survival for MF patients in the study was 9.7 years, with five-and ten-year survival rates of 66 percent and 49 percent, respectively [7] .
No clear etiology for CTCL has been identified. Early investigations postulated that chronic antigenic stimulation of lymphocytes in the form of exposure to environmental agents such as industrial chemicals, metals, pesticides, and tobacco predisposed to the development of CTCL by promoting the malignant transformation of affected lymphocytes [8] . These theories, however, have not been supported by recent case-control studies [9, 10] . The possibility of a retroviral etiology also has been considered, due to the association between human lymphotropic virus type-I (HTLV-1) and T-cell leukemias. Although most patients with CTCL have negative serologies for HTLV-1, viral particles have been isolated from the peripheral blood of some CTCL patients; thus, the role of HTLV-1 in CTCL is still uncertain [11] . An association between CTCL and Epstein-Barr virus has also been reported [12] . Additionally, mutations of the tal-1 and NFKB2/lyt-10 encoded transcription factors have been found in a subset of patients with aggressive disease [3] .
The pathological features of CTCL typically correspond to the developmental stage of the lesions. Biopsies [8] . The predominant cell type in CTCL is the CD4+ helper T-cell, which expresses cutaneous lymphoid antigen (CLA), a P-selectin cell surface glycoprotein that binds to E-selectin on endothelial cells in the skin [12] . CLA as well as interferon elaborated by both neoplastic and normal T-cells facilitate the epidermotropism of the tumor cells. With further disease progression, epidermotropism is often lost, and tumor nodules involving the dermis and subdermal structures are observed.
Differentiating CTCL from a benign inflammatory reaction may be difficult. Phenotypically, both may show loss of CD7 and Leu-8 markers while retaining CD3 and CD4 positivity [8] . However, the expression of activation and proliferation antigens (CD25, CD30, HLA-DR or Ki-67) and the loss of pan T-cell antigens suggest neoplastic progression. Monoclonality can be demonstrated by T-cell receptor gene rearrangement analysis, a process whereby DNA from biopsy specimens is extracted, digested with restriction enzymes, amplified by the polymerase chain reaction, and fractionated on an agarose gel [13, 14] . These techniques have proven to be extremely useful in supporting a diagnosis of CTCL in very early stages when histological changes are often nonspecific [15, 16] . The identification of a Tcell rearrangement signifies the existence of dominant clone, though not necessarily a malignant one. Clonality alone is not sufficient for the diagnosis of malignancy; certain conditions such as Waldenstrom's macroglobulinemia may be caused by a monoclonal lymphocyte population. Hence, evidence from T-cell receptor gene rearrangement studies must be interpreted within the larger context of clinical and pathological findings [8] .
The most widely used staging system for CTCL emphasizes the tumor-nodemetastasis (TNM) classification (Table 1 ) [17] . Essentially, the first three phases of disease correspond to TI or T2 disease, while the tumor phase is T3. Erythroderma is always considered T4 disease. Table 2 shows the stage groupings of MF based on TNM status [17] .
The treatment of MF includes a variety of modalities [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . An evaluation of tumor burden, atypia, and immunocompetence is essential before the initiation of therapy, which consists of three broad categories: skin-directed therapy, biological response modifiers, and chemotherapy 
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Visceral involvement (must have pathology confirmation and organ involved should be specified) a The complete classification contains a category in which the number of circulating atypical cells are noted. This category, however, has never been used for the clinical staging and is, therefore, not included here. It has been demonstrated that it is a useful parameter in this classification except in T4 disease [16] .
b Pathology of Ti -4 is diagnostic of CTCL. When more than one T stage exists, both are recorded, and the highest is used for staging (e.g., T4) [3] . Mi [28] . Skin-directed therapies are most effective in early disease and are the first line treatment for T1-T3 stage disease. They include steroids, topical nitrogen mustard (mechlorethamine), carmustine (BCNU), retinoids, phototherapy with ultraviolet A light (PUVA), and radiotherapy, which includes both x-ray and electron beam therapy. Skin-directed therapy may be used alone or concurrently with other therapies. Biological response modifiers target abnormal T-cell function and altered cytokine profiles observed in MF. Extracorporeal photochemotherapy is presently employed for T4 disease, and trials with other agents such as retinoids, cytokines, immunotoxins, and vaccines are under way [28] . Since biological response agents are typically used for refractory or advanced disease, they are often administered in conjunction with skin-directed therapies. Chemotherapeutic agents used in MF include methotrexate, and T-cell specific agents such as adenosine deaminase inhibitors also have been used in advanced disease [28, 29] .
Recent studies by Wilson et. al., have identified a subset of T2 MF patients who fail after 2.5 or more years following total skin electron beam therapy [25, 30] . It [13] .
RESULTS

Clinical results
Disease-free survival (DFS) was calculated from the end of TSEBT until the time of relapse, which, for each of the patients in the study, was biopsy-documented after examination by the radiation oncologist or the dermatologist. As Table 4 indicates, the median follow-up from the completion of TSEBT for the patients in the study was 3593 days, with a median disease-free interval from the completion of TSEBT was 1222 days. After relapse, two patients received PUVA therapy, one received an additional course of TSEBT, and one received ECP and limited electron beam therapy. Three of the four patients achieved a second CR, while one achieved a partial response. During the course of follow-up, one patient was noted to have a basal cell carcinoma and a squamous cell carcinoma. Another developed a melanoma in situ and a basal cell carcinoma. At the time of analysis, the patients had an overall survival of 100 percent.
TCR gene rearrangement study results
The results of the TCR gamma gene rearrangements for both original and recurrent biopsy specimens along with DNA markers are shown (Figure 1) [13] . Thus, there is a small possibility that the assay was not able to detect the TCR rearrangement in selected samples. This lack of sequence homology between the consensus primers and the conserved portions of the TCR gene could be due to the selection of unanticipated V segments or mutation in response to antigen stimulation [35] . Another factor contributing to the presence of multiple clones is the existence of more than one neoplastic cell line. Although the likelihood of this is rare, this phenomenon has been documented. Additionally the presence of multiple clones could indicate a high-grade neoplasm. In the case of patient No. 3, whose original biopsy demonstrates monoclonality and recurrent biopsy does not, the possibility of transformation as a result of treatment must also be considered. The most likely explanation for the inability to demonstrate monoclonality in the PCR products, however, rests on the quality and age of the samples themselves. Seventy-five percent of the original biopsy specimens were greater than 10 years old at the time of analysis. Problems associated with difficulty amplifying archival biopsy material greater than five years old due to DNA degradation has been documented [16] . Furthermore, the presence of reactive lymphocytes, which are far greater in number than the clonal malignant cells, may have prevented the detection of a single neoplastic cell line [39] .
If Despite the results of this study, TCR analysis via PCR and gel electrophoresis continues to be of utility in the evaluation of patients with MF when used in conjunction with other diagnostic methods. Given the ambiguity of the clinical presentation of this disease and the difficulty associated with making a definitive diagnosis, the use of this diagnostic modality. may be of particular use in cases with nonspecific clinical, histopathological, and immunophenotyping findings. In this subset of patients who may present with clinical features of MF but with no histopathological nor molecular evidence of disease, TCR gene rearrangement studies via PCR could identify those patients who will need more stringent surveillance and follow-up, since they may be harboring occult neoplasms. Furthermore, in patients with biopsy documentation of recurrent MF, this diagnostic tool, given its cost and indeterminate impact upon therapy, should not be routinely used.
